3 results about "Bovine tuberculosis" patented technology

The invention discloses a method for establishing indirect ELISA (enzyme-linked immunosorbent assay) for detecting mycobacterium bovis Lprl, which comprises the following steps: preparing mycobacterium bovis Lprl protein, taking the purified protein as an antigen, and determining conditions such as optimal antigen coating concentration, serum dilution, serum incubation time, secondary antibody dilution concentration, incubation time and the like. The established indirect ELISA detection method does not have cross reaction with other bovine pathogens, the specificity is good, the detection accuracy is high, and the total coincidence rate of test results of intradermal allergy with bovine tubercle bacillus is 95.8%; the intra-batch variation coefficient of the detected samples is 2.43%-3.61%, the inter-batch variation coefficient is 2.83%-3.96%, and the intra-batch variation coefficient and the inter-batch variation coefficient are both smaller than 10%. A new diagnosis target is developed, the established indirect ELISA method has the characteristics of high sensitivity, strong specificity, good repeatability and the like, the operation is easy, and a new method is provided for the detection work of the mycobacterium bovis.

This invention discloses the application of the TRIM58 gene in regulating host resistance to Mycobacterium bovis infection. A bovine macrophage cell line with TRIM58 gene knockout was constructed using CRISPR / Cas9 technology. Results showed that TRIM58 knockout significantly inhibited intracellular survival of Mycobacterium bovis and reduced infection-induced cell death; reintroduction or overexpression of TRIM58 restored or enhanced bacterial viability. Therefore, this invention is the first to demonstrate that TRIM58 is a negative regulator of host resistance to Mycobacterium bovis infection, and that inhibitors of the TRIM58 gene can be used to prepare drugs against Mycobacterium bovis infection or to treat bovine tuberculosis. This invention fills a research gap in the field of TRIM58 in bovine tuberculosis and provides an effective tool for screening and studying the mechanisms of action of anti-bovine tuberculosis drugs.

This invention discloses NmrAL2_Bovine The application of genes as targets in the prevention and control of bovine tuberculosis, including knockout or knockdown. NmrAL2_ Bovine The gene can significantly inhibit the survival of Mycobacterium bovis, Mycobacterium tuberculosis, Mycobacterium bovis BCG, and Mycobacterium smegmae in host cells without affecting the normal proliferation of host cells. Therefore, NmrAL2_Bovine Gene inhibitors can be used to prepare drugs for the prevention and treatment of bovine tuberculosis. NmrAL2_Bovine Genes can also be used as targets in the design of transgenic cattle for breeding against bovine tuberculosis or for genetic therapy research.